Fabry S Disease clinical trials

Explore recruiting fabry s disease clinical trials.

Also recruiting in Europe

Fabry S Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Multi-centre, Open-label Trial to Assess the SaFety, Pharmacodynamics, Efficacy and Pharmacokinetics of PegunigaLsidase Alfa in Patients from 2 Years to Less Than 18 Years of Age with Confirmed FabrY Disease (FLY)

France, Spain, Norway, Austria

Phase II and Phase III (Integrated) EU CTIS Study details

Long-Term Follow-up of Fabry Disease Subjects who were Treated with ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects with Fabry Disease.

Italy, Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alpha (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks in Patients with Fabry Disease

Czechia, Italy, Norway, Belgium, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

Low dose corticosteroids adjacent to enzyme replacement therapy or chaperon therapy in patients with cardiac manifestation of Fabry disease – prospective randomized controlled phase III trial

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12-month Treatment with Migalastat in Pediatric Subjects (aged 2 to < 12 years) with Fabry Disease and Amenable GLA Variants

Spain, Germany, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

Fabry S Disease trials by city

Fabry S Disease in Toronto Fabry S Disease in Vancouver Fabry S Disease in Montreal Fabry S Disease in Calgary Fabry S Disease in Edmonton Fabry S Disease in Ottawa Fabry S Disease in Winnipeg Fabry S Disease in Quebec City Fabry S Disease in Hamilton Fabry S Disease in Kitchener Fabry S Disease in London Fabry S Disease in Halifax Fabry S Disease in New York Fabry S Disease in Los Angeles Fabry S Disease in Chicago Fabry S Disease in Houston

Fabry S Disease clinical trials

Also recruiting in Europe

Multi-centre, Open-label Trial to Assess the SaFety, Pharmacodynamics, Efficacy and Pharmacokinetics of PegunigaLsidase Alfa in Patients from 2 Years to Less Than 18 Years of Age with Confirmed FabrY Disease (FLY)

Long-Term Follow-up of Fabry Disease Subjects who were Treated with ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy

A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects with Fabry Disease.

Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alpha (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks in Patients with Fabry Disease

Low dose corticosteroids adjacent to enzyme replacement therapy or chaperon therapy in patients with cardiac manifestation of Fabry disease – prospective randomized controlled phase III trial

An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12-month Treatment with Migalastat in Pediatric Subjects (aged 2 to < 12 years) with Fabry Disease and Amenable GLA Variants

Fabry S Disease trials by city

Other conditions